Small molecules modulating RNA splicing: a review of targets and future perspectives
- 11 January 2024
- journal article
- review article
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 15 (4) , 1109-1126
Abstract
In eukaryotic cells, RNA splicing is crucial for gene expression. Dysregulation of this process can result in incorrect mRNA processing, leading to aberrant gene expression patterns. Such abnormalities are implicated in many inherited diseases and cancers. Historically, antisense oligonucleotides, which bind to specific RNA targets, have been used to correct these splicing abnormalities. Despite their high specificity of action, these oligonucleotides have drawbacks, such as lack of oral bioavailability and the need for chemical modifications to enhance cellular uptake and stability. As a result, recent efforts focused on the development of small organic molecules that can correct abnormal RNA splicing event under disease conditions. This review discusses known and potential targets of these molecules, including RNA structures, trans-acting splicing factors, and the spliceosome – the macromolecular complex responsible for RNA splicing. We also rely on recent advances to discuss therapeutic applications of RNA-targeting small molecules in splicing correction. Overall, this review presents an update on strategies for RNA splicing modulation, emphasizing the therapeutic promise of small molecules.Keywords
Funding Information
- Fondation pour la Recherche Médicale (AJE202310017978)
This publication has 154 references indexed in Scilit:
- Towards understandings of serine/arginine-rich splicing factorsActa Pharmaceutica Sinica B, 2023
- Design, Synthesis, and Evaluation of Neomycin‐Imidazole Conjugates for RNA CleavageChempluschem, 2022
- RNA‐PROTACs: Degraders of RNA‐Binding ProteinsAngewandte Chemie International Edition, 2020
- Risdiplam: First ApprovalDrugs, 2020
- The SF3b complex: splicing and beyondCellular and Molecular Life Sciences, 2020
- Eteplirsen: First Global ApprovalDrugs, 2016
- Modulating splicing with small molecular inhibitors of the spliceosomeWIREs RNA, 2016
- Bottom‐up Design of Small Molecules that Stimulate Exon 10 Skipping in Mutant MAPT Pre‐mRNAChemBioChem, 2014
- A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumorsInvestigational New Drugs, 2013
- Splicing biomarkers of disease severity in myotonic dystrophyAnnals of Neurology, 2013